Japan is the world’s third-largest economy and home to global industry leaders in areas such as automation and medical tech. However, many companies remain under-researched, so those prepared to explore lesser-known areas of the market can find promising stories. I believe that a rigorous, bottom-up approach to active management can consistently identify companies where the market is underestimating or mispricing future growth, or there is a clear disconnect between near-term sentiment and mid-to-long-term fundamentals.
I tend to invest in small and medium-sized growth companies where I can find better business models and returns on equity, and management is more incentivised in terms of shareholder returns. Smaller companies, being relatively young and dynamic, are often able to create their own niche market and so may be able to grow regardless of the economic backdrop. Managers like myself, based here in Japan, have the opportunity not only to invest in established global leaders, but also to unearth less well-known companies (sometimes before they are listed), where lower levels of analyst coverage can often lead to great mispriced opportunities.
A great translation tool
Rozetta (Tokyo: 6182) offers online machine translation services – faster than human translators, at a tenth of the cost – to sectors including the medical, financial and legal industries. Its business metrics are impressive, with limited churn and high annual recurring revenues. It is shortly coming out with a new suite of products which should help it to penetrate the corporate manual market and is enhancing its distribution model to reach new customers. In future, I expect the development of machine-learning translations and even voice-based technology to be invaluable for Japanese companies where limited English language ability can often be a barrier.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
A play on healthier lifestyles
Shimano (Tokyo: 7309) is a global leader in bicycle components and fishing tackle. It is a long-standing, high-quality business with a solid management team which is taking steps to improve its environmental, social and governance (ESG) credentials. It is the dominant brand in the bicycle components market, due to its innovative technologies, high-quality products and strong aftersales service, so it should be a major beneficiary of the rising popularity of cycling in an increasingly environmental and health conscious world (a trend only reinforced by the Covid-19 pandemic and resulting avoidance of public transport). E-bikes also represent a new growth opportunity.
A turnaround medical tech play
Olympus (Tokyo: 7733) is a global leader in gastroenterological endoscopes. It is driving through structural change and improved governance via its “Transform Olympus” restructuring plan. A new chief executive took over in 2019, with a focus on optimising the medical device business, shrinking non-core operations (including the sale of its loss-making camera business), and improving cost controls. Olympus is also launching a new product cycle, featuring a next-generation endoscopy system that enables early detection and diagnosis through enhanced imaging quality. Its shares trade at a discount to its global peers despite these changes, suggesting attractive upside potential.
-
Lloyds axes foreign currency fees for Club Lloyds customersClub Lloyds customers will be able to withdraw their money abroad without incurring any extra fees
-
How to invest during stagflationTrump’s tariffs look poised to push the global economy into a period of stagflation. We look at how to ensure your investments can survive a global slowdown.
-
The star small and mid-cap stocks income investors have overlookedOpinion Thomas Moore, senior investment director, Aberdeen, highlights three company stocks as he shares where he would put his money
-
Falling revenues and mounting debt spell trouble for Jumia TechnologiesStruggling African e-commerce platform Jumia Technologies looks headed for the exit, says Dr Matthew Partridge.
-
Chemring Group: an explosive investment opportunity in defenceEuropean states are raising their military spending, and Chemring Group looks well placed to profit
-
Next reports £1 billion in annual profits for the first time – what's next for the retailer?Clothing retailer Next has become only the fourth member of its sector to surpass £1 billion in annual profits. What does this mean for the company's future?
-
Best of British bargains: cash in on undervalued companies in the UK stock marketOpinion Michael Field, Chief Equity Market Strategist, EMEA, Morningstar, selects three attractive UK stocks where he'd put his money
-
Building firm Keller presents low debt and ample scope for growthGeotechnical contractor Keller, which supports vital global infrastructure, boasts rising profits and a cheap valuation
-
PZ Cussons share price down 75% in last decade – why it's one to watchOpinion Once-strong consumer-goods business PZ Cussons is out of favour with the market. That spells opportunity for investors, says Jamie Ward
-
Cash in on the biotech sector with specialist trust BioPharmaOpinion BioPharma has an attractive niche in lending to asset-rich biotechnology companies
